How do medical doctors use a web-based oncology protocol system? A comparison of Australian doctors at different levels of medical training using logfile analysis and an online survey

BACKGROUND: Electronic decision support is commonplace in medical practice. However, its adoption at the point-of-care is dependent on a range of organisational, patient and clinician-related factors. In particular, level of clinical experience is an important driver of electronic decision support uptake. Our objective was to examine the way in which Australian doctors at different stages of medical training use a web-based oncology system (http://www.eviq.org.au). METHODS: We used logfiles to examine the characteristics of eviQ registrants (2009–2012) and patterns of eviQ use in 2012, according to level of medical training. We also used a web-based survey to evaluate the way doctors at different levels of medical training use the online system and to elicit perceptions of the system’s utility in oncology care. RESULTS: Our study cohort comprised 2,549 eviQ registrants who were hospital-based medical doctors across all levels of training. 65% of the cohort used eviQ in 2012, with 25% of interns/residents, 61% of advanced oncology trainees and 47% of speciality-qualified oncologists accessing eviQ in the last 3 months of 2012. The cohort accounted for 445,492 webhits in 2012. On average, advanced trainees used eviQ up to five-times more than other doctors (42.6 webhits/month compared to 22.8 for specialty-qualified doctors and 7.4 webhits/month for interns/residents). Of the 52 survey respondents, 89% accessed eviQ’s chemotherapy protocols on a daily or weekly basis in the month prior to the survey. 79% of respondents used eviQ at least weekly to initiate therapy and to support monitoring (29%), altering (35%) or ceasing therapy (19%). Consistent with the logfile analysis, advanced oncology trainees report more frequent eviQ use than doctors at other stages of medical training. CONCLUSIONS: The majority of the Australian oncology workforce are registered on eviQ. The frequency of use directly mirrors the clinical role of doctors and attitudes about the utility of eviQ in decision-making. Evaluations of this kind generate important data for system developers and medical educators to drive improvements in electronic decision support to better meet the needs of clinicians. This end-user focus will optimise the uptake of systems which will translate into improvements in processes of care and patient outcomes

Computerized Clinical Decision Support Systems for decision support in patients with breast, lung, colorectal or prostate cancer

Sistemes electrònics; Càncer; Presa de decisionsSistemas electrónicos; Cáncer; Toma de decisionesElectronic systems; Cancer; Decision makingEl objetivo general de este informe de ETS es evaluar la seguridad, eficacia, efectividad y eficiencia de los sistemas electrónicos de apoyo a las decisiones clínicas (computerized Clinical Decision Support Systems o cCDSS), específicamente de los considerados de nivel medio (p. ej. calculadoras pronósticas o GPC automatizadas) y de nivel alto (aquellos que utilizan la IA para formular recomendaciones específicas para un paciente), para el apoyo a la toma de decisiones clínicas relativas al manejo terapéutico, seguimiento o pronóstico de pacientes con cáncer de mama, pulmón, colon-recto o próstata. También se propone evaluar el impacto de los cCDSS en cáncer a nivel organizativo, legal, ético y social/de pacientes.L'objectiu general d'aquest informe d'ETS és avaluar la seguretat, eficàcia, efectivitat i eficiència dels sistemes electrònics de suport a les decisions clíniques (computeritzed Clinical Decision Support Systems o cCDSS), específicament dels considerats de nivell mitjà (p. ex. calculadores pronòstiques o GPC automatitzades) i de nivell alt (aquells que utilitzen la IA per formular recomanacions específiques per a un pacient), per al suport a la presa de decisions clíniques relatives al maneig terapèutic, seguiment o pronòstic de pacients amb càncer de mama, pulmó, còlon-recte o pròstata. També es proposa avaluar l'impacte dels cCDSS en càncer a nivell organitzatiu, legal, ètic i social/de pacients.The overall objective of this HTA report is to evaluate the safety, efficacy, effectiveness, and efficiency of (computeritzed Clinical Decision Support Systems (cCDSS), specifically those considered medium level (e.g. prognostic calculators or automated CPGs) and high level (those that use AI to formulate patient-specific recommendations), for clinical decision support regarding the therapeutic management, follow-up, or prognosis of patients with breast, lung, colon-rectum or prostate cancer. It is also proposed to assess the impact of cCDSS in cancer at organizational, legal, ethical, and social/patient level